Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_3
10
100%

Phase Distribution

0

Early Stage

0

Mid Stage

10

Late Stage

Phase Distribution10 total trials
Phase 3Large-scale testing
10(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 310 (100.0%)

Trials by Status

completed880%
terminated220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

NCT00432614
terminatedphase_3

Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder

NCT00397098
completedphase_3

Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder

NCT00252343
terminatedphase_3

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder

NCT00535340
completedphase_3

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression

NCT00319709
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00432614Phase 3

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

Completed
NCT00397098Phase 3

Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder

Terminated
NCT00252343Phase 3

Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder

Completed
NCT00535340Phase 3

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder

Terminated
NCT00319709Phase 3

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression

Completed
NCT00266747Phase 3

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

Completed
NCT00252330Phase 3

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

Completed
NCT00252356Phase 3

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

Completed
NCT00345098Phase 3

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder

Completed
NCT00332891Phase 3

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10